Last reviewed · How we verify
Prevention of CMV Disease in Advanced HIV Patients — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Cytovene | GANCICLOVIR | Roche Palo | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor | Metabotropic glutamate receptor 1 | 1989-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Roche Palo · 1 drug in Prevention of CMV Disease in Advanced HIV Patients
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prevention of CMV Disease in Advanced HIV Patients:
- Prevention of CMV Disease in Advanced HIV Patients treatment updates — RSS
- Prevention of CMV Disease in Advanced HIV Patients treatment updates — Atom
- Prevention of CMV Disease in Advanced HIV Patients treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prevention of CMV Disease in Advanced HIV Patients — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-cmv-disease-in-advanced-hiv-patients. Accessed 2026-06-10.
Related
- Prevention of CMV Disease in Advanced HIV Patients full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing